A Phase 3, Open-Label Study with Asunaprevir and Daclatasvir Plus Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) (P/R) (QUAD) for Subjects Who Are Null or Partial Responders to Peginterferon Alfa 2a or 2b Plus Ribavirin with Chronic Hepatitis C Genotypes 1 or 4 Infection - Hallmark QUAD

BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO0 个研究点目标入组 520 人开始时间: 2012年6月12日最近更新: 2014年2月10日

适应症

试验速览

暂无简介。

•Males and females, = 18 years of age; • HCV Genotype 1 or 4 who previously failed treatment with P/R, classified as previous null and partial responders based on previous therapy; • HCV RNA = 10,000 IU/mL; • Seronegative for HIV and HBsAg; • Subjects with compensated cirrhosis are permitted (compensated cirrhotics are capped at approximately 25% of treated population).
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 500
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 20

•Prior treatment of HCV with HCV direct acting antiviral (DAA); • Evidence of a medical condition contributing to chronic liver disease other than HCV; • Evidence of decompensated liver disease including, but not limited to, a history or presence of ascites, bleeding varices, or hepatic encephalopathy; • Diagnosed or suspected hepatocellular carcinoma or other malignancies; • Uncontrolled diabetes or hypertension; • Total bilirubin = 34 µmol/L (or = 2 mg/dL) unless subject has a documented history of Gilbert's disease; • Confirmed ALT = 5x ULN; • Confirmed Albumin < 3.5 g/dL (35 g/L) • AFP > 100 ng/mL OR = 50 and = 100 ng/mL requires a liver ultrasound and subjects with findings suspicious of HCC are excluded; • ANC < 1.5 x 10 billion cells/L (< 1.2 x 10 billion cells/L for Black/African-Americans); • Confirmed Platelets < 90 x 10 billion cells/L; • Hemoglobin < 12 g/dL for females or < 13 g/dL for males; • Any criteria that would exclude the subject from receiving P/R.

发起方